SCHEMBL937463

SCHEMBL937463

CNC(=O)c1cc(Oc2cc(N(C=O)Nc3ccc(Br)c(C(F)(F)F)c3)ccc2C)ccn1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAF1 P04049 14/20 0.58
MAPK14 Q16539 4/20 0.49
MAP3K20 Q9NYL2 4/20 0.49
BRAF P15056 7/20 0.46
KDR P35968 6/20 0.46
RET P07949 4/20 0.46
EPHX2 P34913 3/20 0.46
ABL1 P00519 3/20 0.46
EPHA2 P29317 3/20 0.46
AURKB Q96GD4 3/20 0.46
SRC P12931 3/20 0.46
RIPK2 O43353 2/20 0.46
ABCB11 O95342 2/20 0.46
HTR1A P08908 2/20 0.46
PDGFRB P09619 2/20 0.46
ADORA3 P0DMS8 2/20 0.46
KIT P10721 2/20 0.46
FGFR1 P11362 2/20 0.46
PDGFRA P16234 2/20 0.46
FLT1 P17948 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL939153 0.88 RAF1 (0.63) RAF1MAPK14MAP3K20BRAFKDR
SCHEMBL939118 0.79 RAF1 (0.49) RAF1MAPK14MAP3K20BRAFKDR
SCHEMBL938508 0.78 RET (0.69) RAF1MAPK14MAP3K20BRAFKDR
SCHEMBL936626 0.76 RAF1 (0.65) RAF1MAPK14MAP3K20BRAFKDR
SCHEMBL549001 0.74 RAF1 (1.00) RAF1MAPK14MAP3K20BRAFKDR
SCHEMBL1506322 0.74 RAF1 (0.78) RAF1MAPK14MAP3K20BRAFKDR
SCHEMBL1506420 0.73 RAF1 (0.86) RAF1MAPK14MAP3K20BRAFKDR
SCHEMBL939154 0.72 RAF1 (0.62) RAF1MAPK14MAP3K20BRAFKDR
SCHEMBL7967866 0.72 RAF1 (0.55) RAF1MAPK14MAP3K20BRAFKDR
SCHEMBL5137329 0.72 RAF1 (0.67) RAF1MAPK14MAP3K20BRAFKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10653684-B2 Aryl ureas with angiogenisis inhibiting activity BAYER HEALTHCARE LLC (US) 2020-05-19 US disclosed
US-20180296541-A9 ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY BAYER HEALTHCARE LLC (US) 2018-10-18 US disclosed
US-20160015697-A1 ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY BAYER HEALTHCARE LLC (US) 2016-01-21 US disclosed
US-8618141-B2 Aryl ureas with angiogenesis inhibiting activity BAYER HEALTHCARE LLC (US) 2013-12-31 US disclosed
US-20120289552-A1 ARYL UREAS WITH ANGIOGENESIS INHIBITING ACTIVITY BAYER HEALTHCARE LLC (US) 2012-11-15 US disclosed
US-8242147-B2 Aryl ureas with angiogenisis inhibiting activity BAYER HEALTHCARE LLC (US) 2012-08-14 US disclosed
EP-1636585-B2 DIARYL UREAS WITH KINASE INHIBITING ACTIVITY BAYER HEALTHCARE LLC (US) 2012-06-13 EP disclosed
EP-2324825-A1 Aryl ureas with angiogenesis inhibiting activity Bayer Healthcare LLC (US) 2011-05-25 EP disclosed
EP-2289515-A2 Combinations comprising a diaryl urea and an interferon Bayer HealthCare LLC (US) 2011-03-02 EP disclosed
US-20110015195-A1 ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY DUMAS JACQUES 2011-01-20 US disclosed
US-7838541-B2 Aryl ureas with angiogenesis inhibiting activity BAYER HEALTHCARE, LLC (US) 2010-11-23 US disclosed
US-20090068146-A1 DIARYL UREAS AND COMBINATIONS BAYER PHARMACEUTICALS CORPORATION 2009-03-12 US disclosed
US-20080227828-A1 Aryl Ureas With Angiogenisis Inhibiting Activity BAYER HEALTHCARE LLC 2008-09-18 US disclosed
EP-1636585-B1 DIARYL UREAS WITH KINASE INHIBITING ACTIVITY BAYER PHARMACEUTICALS CORP (US) 2008-01-16 EP disclosed
US-20070020704-A1 Diaryl ureas with kinase inhibiting activity BAYER HEALTHCARE LLC 2007-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180296541-A9 ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY FLT1, FLT4, KDR RAF1 867/4885MAPK14 445/4885MAP3K20 177/4885
US-20070020704-A1 Diaryl ureas with kinase inhibiting activity FLT4, FLT1, FLT3 RAF1 51/4885MAPK14 120/4885MAP3K20 10/4885
US-10653684-B2 Aryl ureas with angiogenisis inhibiting activity FLT1, FLT4, KDR RAF1 867/4885MAPK14 445/4885MAP3K20 177/4885
US-20110015195-A1 ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY FLT1, FLT4, KDR RAF1 867/4885MAPK14 445/4885MAP3K20 177/4885
US-20080227828-A1 Aryl Ureas With Angiogenisis Inhibiting Activity FLT1, FLT4, KDR RAF1 867/4885MAPK14 445/4885MAP3K20 177/4885
US-20090068146-A1 DIARYL UREAS AND COMBINATIONS NR4A1, NAP1L4, NR4A3 RAF1 4118/4885MAPK14 3979/4885MAP3K20 4329/4885
US-20120289552-A1 ARYL UREAS WITH ANGIOGENESIS INHIBITING ACTIVITY FLT4, FLT1, KDR RAF1 817/4885MAPK14 380/4885MAP3K20 113/4885
US-20160015697-A1 ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY FLT1, FLT4, KDR RAF1 867/4885MAPK14 445/4885MAP3K20 177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.